CME Sponsor:
MS-Leaders.org

Location:
Web-based material

Course Directors/Instructors:
Johns Hopkins Co-Chairs:
Scott Newsome, DO
Assistant Professor of Neurology
Johns Hopkins University School of Medicine
Baltimore, MD

John Ratchford, MD
Assistant Professor of Neurology
Johns Hopkins University School of Medicine
Baltimore, MD

Moderator
Benjamin M. Greenberg, MD, MHS
Director, Transverse Myelitis and Neuromyelitis Optica Program
Deputy Director, Multiple Sclerosis Program
Cain Denius Scholar in Mobility Disorders
Department of Neurology UT Southwestern
Dallas, TX

Faculty
Rohit Bakshi, MD, FAAN
Professor of Neurology
Brigham & Women's Hospital, Harvard Medical School
Director, Laboratory for Neuroimaging Research
Partners MS Center
Boston, MA

Steven L. Galetta, MD
Ruth Wagner Van Meter and J. Ray Van Meter Professor of Neurology
Director
Neuro-ophthalmology Services
University of Pennsylvania
Philadelphia, PA

Number of Credits:
1.5 AMA PRA Category 1 Credits™

Registration Fee: Free

More Info

Detailed Description:
The classic diagnosis of multiple sclerosis (MS) requires evidence of inflammatory demyelination of the CNS, which is disseminated in both space and time.  Confidently making the diagnosis following a single episode of optic neuritis, brainstem syndrome or partial myelitis -- the clinically isolated syndromes (CIS) -- should be the goal of contemporary care, as clear benefit can now be offered through early therapy.  By building on the pre-MRI criteria of Poser, and using enhancements proposed by others in the 1980s, 1990s, and 2000, the more widely-accepted McDonald criteria were developed in 2001 and revised in 2005.  More recently, advancements have been suggested that strive to make diagnostic criteria simpler, while decreasing possible delay in the institution of effective therapy.

Learning Objectives:
After viewing the program, the participant should demonstrate the ability to:
  • Outline the currently accepted and proposed criteria for the diagnosis of MS following a presentation of CIS
  • Explain how newer proposed criteria may simplify MS diagnosis by enabling a diagnosis to be made after a single clinical event
  • Recall that the long-term outcome of high-risk CIS is similar to clinically definite MS
  • Discuss the benefit of early treatment of high-risk CIS over delayed treatment based upon results of several recent clinical trials
  • Recognize the ‘radiologically isolated syndrome’
Intended Audience:
Health care professionals with roles in the diagnosis and treatment of clinically isolated syndrome and multiple sclerosis